Mobile

A clinical trial of axitinib plus PF-04856884 or axitinib alone for patients with metastatic renal cancer who have already been treated with an anti-VEGF agent

Mise à jour : Il y a 4 ans
Référence : EUCTR2011-002190-33

Femme et Homme

  • | Pays :
    • -
  • | Organes :
    • -
  • | Spécialités :
    • -

Extrait

Part I: To confirm that the combination of PF-04856884 and AG-013736 is safe and tolerable at the doses to be used in Part II of the study. Part II: To document clinical activity of the combination of PF-04856884 and AG-013736 or AG-013736 alone as measured by PFS in adult patients with previously treated mRCC.

Critère d'inclusion

  • Metastatic Renal Cell Carcinoma

Liens